GlassScriptPhysician profile
Liezel M De Guzman
NPI 1548839228
$2,005.41
in general payments reported to CMS, 2019-2025
18 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.18 · 2022: $266 · 2023: $411 · 2024: $263 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $588.99 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $379.95 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $243.77 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $169.25 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $121.54 | 2023-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.51 | 2022-2025 | Jardiance |
| Dexcom, INC. | $82.48 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $54.21 | 2022-2023 | |
| Corcept Therapeutics | $46.91 | 2025 | Korlym |
| Hologic Sales and Service, LLC | $43.58 | 2025 | Aptima |
| Amgen INC. | $34.16 | 2023-2024 | Repatha, Otezla |
| Pfizer INC. | $28.02 | 2025 | |
| Verity Pharmaceuticals INC. | $25.63 | 2025 | Tlando |
| Mannkind Corporation | $20.75 | 2023 | Afrezza |
| Esperion Therapeutics, INC. | $20.48 | 2025 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $20.00 | 2022 | |
| Ibsa Pharma INC. | $20.00 | 2022 | |
| Eisai INC. | $17.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liezel De Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.